Interní Med. 2018; 20(4): 198-200 | DOI: 10.36290/int.2018.059
Obesity treatment and experience with a centrally-acting antiobesity agent?
- Centrum pro léčbu obezity a metabolických poruch, OB klinika, a. s., Praha
The article briefly summarizes the development of antiobesity drugs from the beginning of use to the present and introduces anovel dual-combination agent with central dual action. A noninterventional, observational, multidisciplinary trial of the use ofthe new drug will be presented in two parts. In this issue, we deal with its three-month efficacy, and the next one will present asummary of six-month administration including adverse effects and some patient opinions of the novel therapy.
Keywords: obesity, BMI, pharmacotherapy for obesity, diabetes mellitus
Received: April 17, 2018; Accepted: May 9, 2018; Prepublished online: May 9, 2018; Published: October 1, 2018 Show citation
References
- Finucane MM, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011; 377: 557-567.
Go to original source... 
Go to PubMed... - World Health Organization (WHO), available at: http://www.euro.who.int/en/what-wedo/health-topics/noncommunicable-diseases/obesity. Accessed April 2013.
- World Health Organization (WHO), Fact Sheet No.311 (updated March 2013) available at: http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed April 2013.
- Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes (London). 2008; 32: 1431-1437. Go to original source... Go to PubMed...
- Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013; 273: 219-234. Go to original source... Go to PubMed...